Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2,3,3,4,4,5,5-d7-2-carboxamide
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 95 %
Hazard Compound
No -Refer MSDS for accurate information
Alfuzosin-d7 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Alfuzosin-d7 usage and description
Alfuzosin D7 is a deuterated form of the medication alfuzosin, which is primarily used to treat symptoms associated with an enlarged prostate gland, such as difficulty urinating and frequent urination. Alfuzosin D7 is commonly used in research and development studies as an analytical standard to determine the pharmacokinetics of alfuzosin in biological fluids.
The chemical structure of Alfuzosin D7 is similar to alfuzosin, with the only difference being the presence of seven deuterium atoms in the molecular structure. Deuterium is a stable isotope of hydrogen, and its presence in Alfuzosin D7 enhances the accuracy of the analytical measurements due to its unique mass properties.
Alfuzosin D7 is typically administered orally in the form of extended-release tablets, with a recommended dosage of 10 mg once daily. The medication works by relaxing the muscles in the prostate gland and bladder neck, thereby improving urine flow and reducing the symptoms associated with an enlarged prostate.
Studies have shown that Alfuzosin D7 is well-tolerated by most patients, with minimal side effects such as dizziness, headache, and fatigue. However, it is important to note that alfuzosin may interact with other medications, such as alpha-blockers, nitrates, and antihypertensives, and should only be used under the supervision of a healthcare professional.
